Growing up, Sara-Catherine Bellamy's mom always made the holidays incredibly special for her family. This year, as the ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

The following is a summary of “Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site ...

No writing assistance was utilized in the production of this manuscript. Ocular surface squamous neoplasia is the most common nonpigmented ocular surface lesion. Ocular surface squamous neoplasia ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

Opens in a new tab or window The FDA approved cosibelimab (Unloxcyt) for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults who are not candidates for ...

Checkpoint Therapeutics, Inc. announced that the FDA has approved UNLOXCYT™ (cosibelimab-ipdl) for treating adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...